Why Gynecologic Oncologists Get Sued: The Missed Cancer and the Ureter in the Field

By John Mahoney · June 2026 · 8 min read

Gynecologic oncology is one of the few specialties where a single physician carries two entirely different liability profiles at once. As a diagnostician, the gynecologic oncologist sits at the end of a long referral chain for cervical, endometrial, ovarian, and vulvar cancers — and a missed or delayed diagnosis there compounds into the highest-severity claims in women's health. As a surgeon, that same physician performs radical pelvic operations in a field crowded with the ureter, bladder, bowel, and great vessels, where a single intraoperative injury can anchor a serious claim regardless of the cancer outcome. An attorney who screens a gynecologic oncology intake as if it were a routine OB/GYN file will misjudge both the merit and the value. This guide explains where the liability actually lives, the cannot-miss failures behind it, and what separates a strong case from a weak one — for plaintiff and defense med-mal attorneys.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. The patterns below draw on closed-claims and insurer datasets that span different eras and definitions; treat them as directional, verify against the controlling jurisdiction, and value any individual case on its own record.

The Frequency-and-Severity Reality

Gynecologic oncology lives inside the broader OB/GYN risk picture, which is a high-frequency, high-severity specialty — obstetrics and gynecology consistently rank among the most-sued fields, and surveys commonly report that the large majority of OB/GYNs face at least one claim during their careers. The oncology sub-specialty narrows the patient population but raises the stakes: the underlying disease is life-threatening, the surgeries are major, and the window in which intervention changes the outcome is finite. A claim here rarely involves a trivial injury.

Severity is where this specialty stands apart. Cancer-diagnosis and oncology-surgery claims are among the costliest categories in medical malpractice generally, and gynecologic cancer claims pull on both. Missed or delayed cancer diagnoses produce the largest payouts because the alleged harm is a worsened prognosis, a more aggressive course of treatment, or death — damages that map directly onto loss-of-chance valuation. Intraoperative injury claims from radical surgery are more variable but can be substantial when an unrecognized ureteral or bowel injury cascades into fistula, reoperation, sepsis, or renal loss. The practical lesson is that two valuation models live inside this one specialty, and an intake must be routed to the right one immediately, because the merit analysis, the experts, and the damages theory are entirely different.

The Dominant Allegation Types

Gynecologic oncology claims cluster into a diagnostic group and a surgical group, with treatment and consent threads running through both:

• Failure to diagnose or delayed diagnosis of cancer — the highest-severity category, covering cervical, endometrial, ovarian, and vulvar cancer, and very often turning on an abnormal Pap, biopsy, or imaging result that was not acted upon.
• Intraoperative injury during radical pelvic surgery — ureteral, bladder, bowel, or vascular injury sustained during hysterectomy, debulking, or lymphadenectomy, particularly when the injury is unrecognized until the postoperative period.
• Chemotherapy dosing and toxicity — dosing errors, failure to monitor or manage toxicity, and extravasation or adverse-reaction injuries in the medical-oncology side of the practice.
• Failure to stage adequately or to recommend appropriate adjuvant therapy — understaging, omitted lymph-node assessment, or failure to offer indicated radiation or chemotherapy that allegedly changed the outcome.
• Lack of informed consent — especially around fertility-sparing-versus-radical decision-making, surgical-injury risks, and the trade-offs of adjuvant treatment.

The structural point: by alleged severity, the diagnostic-delay cases dominate the dollars, but the surgical-injury cases are the ones most likely to present with a discrete, demonstrable mechanism. Any intake should be triaged first on which side of that line it sits, because everything downstream — the standard-of-care expert, the causation theory, and the damages model — follows from that single decision.

The Cannot-Miss Conditions and Failures

The conditions and failures that drive gynecologic oncology litigation are:

• Cervical cancer — missed or delayed. The classic failure is an abnormal Pap or HPV result, or an abnormal colposcopy or biopsy, that was not followed up to definitive diagnosis. These are textbook closed-loop failures, because cervical screening is built around acting on a result.
• Endometrial cancer — missed or delayed. Postmenopausal bleeding that was not worked up with timely biopsy or imaging, or an endometrial biopsy result that was not acted on, drives this category.
• Ovarian cancer — misdiagnosed or delayed. Vague symptoms, a pelvic mass not adequately characterized, or imaging and tumor-marker findings that were not pursued; the late stage at which ovarian cancer is often found makes the delay-causation argument central.
• Vulvar cancer — missed or delayed. A persistent vulvar lesion that was treated symptomatically rather than biopsied, allowing progression.
• Unrecognized intraoperative injury — ureteral, bladder, bowel, or vascular injury during radical surgery that was not identified and repaired during the index operation, leading to fistula, peritonitis, sepsis, reoperation, or loss of renal function.

For the diagnostic side, the single most actionable screening question is the closed-loop question: was an abnormal Pap, biopsy, or imaging result tracked, communicated, and acted on through to definitive diagnosis? A missed-cancer claim very often turns on a result-notification or recall failure rather than a misread under the microscope. For the surgical side, the decisive question is whether the injury was a recognized risk that was promptly identified and managed, or whether the failure was the delayed recognition that turned a manageable injury into a catastrophe.

The Contributing Factors That Drive Payouts

Across gynecologic oncology closed claims, the recurring contributing factors are:

• Clinical judgment and the diagnostic process — the costliest factor: failure to act on an abnormal Pap, biopsy, or imaging result, failure to work up postmenopausal bleeding or a pelvic mass, and breakdowns in result tracking and follow-up that drive the high-severity missed-cancer claims.
• Technical performance and intraoperative recognition — ureteral, bladder, bowel, and vascular injuries during radical surgery, with the most damaging fact being delayed recognition rather than the injury itself, since a promptly identified and repaired injury is often defensible.
• Staging and adjuvant-therapy decisions — inadequate staging, omitted nodal assessment, or failure to recommend indicated radiation or chemotherapy, which feeds a treatment-causation argument.
• Chemotherapy administration and monitoring — dosing errors and failures to recognize or manage toxicity, a distinct medical-oncology exposure separate from the surgical claims.
• Communication, informed consent, and documentation — especially the fertility-sparing-versus-radical conversation, surgical-injury risk disclosure, and the record of how results were reported; thin documentation of consent and result-notification consistently weakens the defense.

Two of these are sub-specialty-specific levers. The first is the result-notification record in the diagnostic cases: the line between a defensible file and a paid claim is often whether the chart shows the abnormal Pap, biopsy, or imaging finding was communicated to the patient and pursued to resolution. The second is the intraoperative-recognition record in the surgical cases: a documented intraoperative identification and repair of a ureteral or bowel injury reframes the case as a known complication competently managed, while a postoperative discovery reframes it as a missed injury. Documentation rarely creates liability here, but it consistently decides whether a claim is paid.

Strong Case vs. Weak Case in Gynecologic Oncology Malpractice

The same factors grade the file, and the framing is useful to both sides.

What makes a gynecologic oncology case strong (plaintiff) / dangerous (defense)

• An abnormal Pap, biopsy, or imaging result that was documented but never followed up to definitive diagnosis, or a postmenopausal-bleeding presentation that was not worked up — a clean closed-loop failure.
• A cancer diagnosed at a materially later stage where earlier action carried a meaningfully better prognosis or survival, supporting a strong loss-of-chance causation theory.
• An unrecognized ureteral, bladder, or bowel injury discovered only postoperatively after the patient developed fistula, sepsis, or required reoperation, with no intraoperative note of identification or repair.
• A radical-versus-fertility-sparing decision made with absent or generic informed consent that did not match the realized outcome, or a failure to recommend indicated adjuvant therapy.

What makes a gynecologic oncology case weak (plaintiff) / defensible (defense)

• An abnormal result that was promptly communicated, tracked, and worked up with appropriate biopsy, imaging, and referral — the closed loop intact.
• A ureteral or bowel injury that was a disclosed, known risk of the procedure, identified intraoperatively and repaired in the same operation with documented consent and counseling, framing the harm as an accepted and competently managed complication.
• A patient whose record shows declined biopsy, missed appointments, or non-adherence that drove the delay in diagnosis.
• Staging, adjuvant-therapy recommendations, and chemotherapy dosing performed and documented to guideline standards, with a clear record of the fertility-versus-radical discussion.

Gynecologic oncology rewards a fast triage. On the diagnostic side, the case lives or dies on the closed loop and the loss-of-chance causation chain — whether earlier diagnosis would have changed the stage, the treatment, or the survival. On the surgical side, it turns on whether the injury was a recognized risk identified and repaired in real time, or a missed injury allowed to cascade. Whichever side you are on, grading the file means matching the right model to the right claim and pressure-testing the expert who will carry it.

Bottom Line

Gynecologic oncologists get sued at the intersection of two of the highest-severity claim types in medicine: missed cancer and surgical injury. The diagnostic claims — cervical, endometrial, ovarian, and vulvar cancer missed because an abnormal Pap, biopsy, or imaging result was not acted on — carry the largest payouts, and they live or die on the closed-loop follow-up and the loss-of-chance causation argument. The surgical claims — ureteral, bladder, bowel, and vascular injury during radical pelvic surgery — turn less on the injury than on whether it was recognized and repaired during the index operation. Layer in chemotherapy toxicity, staging and adjuvant-therapy decisions, and the fertility-sparing-versus-radical consent conversation, and the cannot-miss facts come into focus. Whether you are screening these cases for the plaintiff or defending them, triage first to the right model — diagnostic or surgical — and grade the file on the closed loop, the intraoperative-recognition record, and the documented consent, not on the gravity of the cancer alone.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all 70 specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →